Semaglutide has the largest safety dataset of any GLP-1 receptor agonist — over 57,000 participants across 23 randomized controlled trials (PMID 39046272). The side effect profile is well-characterized and, for most users, manageable with proper dose titration.
This is not medical advice. This article summarizes published clinical trial data on semaglutide's adverse event profile. Always work with a healthcare provider.
The Big Picture: What Trial Data Shows
Across the STEP and SUSTAIN/PIONEER trial programs, the pattern is consistent: gastrointestinal side effects dominate, most are mild-to-moderate, and they decrease with continued use (PMID 36700417).
Here's the breakdown from pooled STEP 1-3 data covering 2,117 semaglutide-treated participants (PMID 34514682):
- 99.5% of GI adverse events were non-serious
- 98.1% were mild-to-moderate in severity
- 4.3% of users permanently discontinued due to GI side effects
- GI events contributed less than 1 percentage point to overall weight loss
The weight loss is not coming from being too nauseous to eat. Mediation analysis confirms GI side effects account for a negligible portion of semaglutide's weight loss effect (PMID 34514682).
Common Side Effects (>10% Incidence)
These affect the majority of users and are considered part of the expected adaptation process.
Nausea — 44% of Users
The most frequent side effect by a wide margin. Nausea typically appears within hours of injection, peaks during dose escalation (weeks 1-8), and subsides as the body adapts. In STEP trials, most nausea episodes were mild and lasted a median of ~8 days (PMID 34514682).
Diarrhea — 30% of Users
Usually intermittent rather than constant. Tends to occur in the first 1-2 days post-injection and resolves between doses. Adequate hydration and electrolyte intake reduce severity.
Vomiting — 25% of Users
Often accompanies nausea, particularly during the first few weeks. The relative risk versus placebo is 4.12x — the highest of any GI side effect (PMID 39046272). Slow titration dramatically reduces incidence.
Constipation — 24% of Users
Semaglutide slows gastric emptying, which can reduce bowel movement frequency. Fiber intake, hydration, and magnesium supplementation help. This effect typically stabilizes after 4-6 weeks.
Decreased Appetite — Common
This is the intended mechanism of action, but some users experience appetite suppression beyond what feels comfortable. If you're struggling to meet minimum caloric needs (under 1,200 kcal/day), discuss dose adjustment with your provider.
Uncommon Side Effects (1-10% Incidence)
Injection Site Reactions — 3-5%
Redness, swelling, or itching at the injection site. Almost always mild and self-resolving within 24-48 hours. Rotate injection sites (abdomen, thigh, upper arm) to minimize occurrence.
Fatigue — 3-5%
More common during the initial weeks when caloric intake drops significantly. Usually resolves as the body adapts to lower energy intake. Ensure adequate protein and micronutrient intake.
Headache — 3-4%
Potentially related to changes in blood sugar regulation or reduced caloric intake. Hydration and consistent meal timing help.
Dizziness — 2-3%
Monitor for hypoglycemia if stacking with other glucose-lowering compounds. More common in individuals with type 2 diabetes on concurrent insulin therapy.
Gallbladder Events — 1-3%
Semaglutide increases the risk of cholelithiasis (gallstones) by approximately 2.6x compared to placebo (PMID 34305810). Rapid weight loss itself is a known risk factor for gallstone formation, so the mechanism may be partially indirect. Report any right upper quadrant pain, especially after meals.
Serious Side Effects (Rare, <1%)
These are uncommon but require immediate medical attention.
Acute Pancreatitis
Meta-analysis shows no statistically significant increase in pancreatitis risk with semaglutide versus placebo (PMID 39046272). However, cases have been reported. Stop immediately if you develop severe, persistent epigastric pain radiating to the back, especially with vomiting. Get lipase levels checked.
Thyroid C-Cell Tumors
Semaglutide carries a boxed warning based on rodent studies showing thyroid C-cell tumors (medullary thyroid carcinoma). This has not been confirmed in humans, and the relevance to human use is uncertain. However, semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Diabetic Retinopathy Complications
In diabetic populations, rapid blood sugar improvements can paradoxically worsen existing diabetic retinopathy. This is not specific to semaglutide but to any treatment that rapidly improves glycemic control. Baseline eye exams are recommended for diabetic users (PMID 34305810).
Hypoglycemia
Rare when semaglutide is used alone. Risk increases when combined with insulin or sulfonylureas. Monitor blood glucose if stacking with other glucose-lowering agents.
